NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

Celurity has completed the sale of its degenerative disease segment to NEXGEL, a transaction that includes a portfolio of six commercial-stage regenerative biomaterial products. The press release does not disclose the financial terms of the sale or the strategic benefits for Celurity, focusing instead on NEXGEL's financing and growth projections.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.